How does Seroquel (quetiapine) affect insulin and blood glucose levels?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 25, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Seroquel (Quetiapine) Significantly Increases Blood Glucose and Impairs Insulin Function

Seroquel (quetiapine) causes hyperglycemia through multiple mechanisms including impaired insulin secretion, increased insulin resistance, and direct effects on pancreatic beta cells, requiring baseline and ongoing glucose monitoring in all patients. 1

Metabolic Effects on Glucose and Insulin

Direct Glucose Effects

According to FDA labeling, quetiapine causes measurable increases in blood glucose levels 1:

  • Adults: Mean fasting glucose increased by +5.0 mg/dL in long-term studies (vs -0.05 mg/dL for placebo)
  • Shift to diabetes range: 2.4% of patients with normal baseline glucose (<100 mg/dL) developed fasting glucose ≥126 mg/dL
  • Borderline glucose worsening: 11.7% of patients with borderline glucose (100-125 mg/dL) progressed to diabetic range (≥126 mg/dL), similar to placebo at 11.8%
  • Exposure-adjusted incidence: 18.0 per 100 patient-years for hyperglycemia (≥126 mg/dL) vs 9.5 for placebo

Mechanisms of Insulin Dysfunction

The evidence reveals quetiapine affects insulin through three distinct pathways:

  1. Reduced Insulin Secretion 2: Quetiapine-treated youth showed significantly lower insulinogenic index (P<0.01) and impaired beta-cell function (ISSI-2, P<0.01) compared to antipsychotic-naive patients. Mouse islet studies confirmed direct suppression of insulin expression by quetiapine.

  2. Increased Insulin Resistance 3, 4: An 8-week prospective study found insulin resistance significantly increased with quetiapine treatment. Cross-sectional data showed insulin sensitivity inversely correlated with quetiapine dose (P=0.0001).

  3. Impaired Glucose Effectiveness 4: Quetiapine reduces the body's ability to dispose of glucose independent of insulin (lower SG values).

Clinical Monitoring Requirements

The 2024 ADA guidelines mandate specific screening protocols for second-generation antipsychotics 5:

  • Baseline: Fasting blood glucose before starting quetiapine
  • Early monitoring: Rescreen at 12-16 weeks after medication initiation
  • Ongoing surveillance: Annual screening thereafter
  • High-risk patients: More frequent monitoring if obesity, family history of diabetes, or other risk factors present

Important Caveat

The guideline notes quetiapine has "more metabolic effects" compared to aripiprazole and ziprasidone, placing it in the higher-risk category alongside haloperidol, clozapine, and risperidone 5.

Dose-Dependent Considerations

Even low-dose quetiapine (25-50 mg tablets) carries metabolic risk, though the relationship is complex 6, 7:

  • A 2021 prospective study found dose-dependent weight gain and lipid alterations with quetiapine 6
  • However, a large Danish cohort study (n=896,285) found no excess diabetes risk with low-dose quetiapine compared to SSRIs after propensity-score matching 7
  • The case-control analysis showed higher daily doses were associated with diabetes (OR 1.08 per doubling, P<0.05) 7

Clinical implication: While low doses may have lower absolute risk, they are not risk-free. Prescribe the minimal effective dose and monitor all patients regardless of dose.

Rare but Severe Presentations

Extreme hyperglycemia with ketoacidosis, hyperosmolar coma, or death has been reported 1. Paradoxically, one case report documented severe hypoglycemia with endogenous hyperinsulinemia in an older patient without diabetes, requiring massive 20% dextrose infusion 8. This resolved only after quetiapine discontinuation.

Management Approach

For Patients Developing Hyperglycemia on Quetiapine

  1. Assess severity: Check fasting glucose, HbA1c, and symptoms (polydipsia, polyuria, polyphagia, weakness) 1

  2. Consider medication adjustment:

    • Switch to lower-risk antipsychotic if clinically feasible: aripiprazole, ziprasidone, lurasidone, brexpiprazole, or cariprazine 9
    • Some patients' diabetes ameliorates with quetiapine discontinuation alone 10
  3. Pharmacologic treatment if diabetes develops 9:

    • First-line: Metformin (also useful for prediabetes prevention)
    • Add-on therapy: GLP-1 receptor agonists (provide weight loss benefit) or SGLT-2 inhibitors
    • Both classes offer cardio-renal benefits beyond glucose control
  4. Manage comorbidities: ACE inhibitors/ARBs for hypertension; statins for dyslipidemia 9

Common Pitfall

Do not rely on lifestyle interventions alone—outcomes have been disappointing in this population 9. Pharmacologic intervention is typically necessary.

Timeline Considerations

Diabetes typically develops after a median of 1.6 years of quetiapine treatment 10, though metabolic changes begin earlier. Nearly all patients who developed quetiapine-associated diabetes had dyslipidemia and increased BMI at diagnosis 10.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.